Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and ...

With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...

Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective analysis.

LBA-1: Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase III Study (inMIND) SAN DIEGO, Dec. 10, 2024 /PRNewswire/ -- Patients with ...

Incyte (INCY) announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab, a humanized Fc-modified ...

Late-breaking data presentation at ASH will feature results from the Phase 3 inMIND study evaluating tafasitamab in follicular lymphoma (FL); data to be highlighted during ASH press program ...

BMO Capital analyst Evan Seigerman maintained a Sell rating on Incyte (INCY – Research Report) yesterday and set a price target of $52.00.Pick ...

This late-breaking presentation provides valuable insights into the potential role of tafasitamab in improving outcomes for FL patients who currently face limited effective treatment options.” ...

Late-breaking data presentation at ASH will feature results from the Phase 3 inMIND study evaluating tafasitamab in follicular lymphoma (FL); data to be highlighted during ASH press program - Incyte ...